Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand

Hims & Hers (HIMS) has surged 45% in the past month and 160% year-to-date, but technical indicators suggest a correction is due. However, a major catalyst looms: employers are planning to drop GLP-1 drug coverage in 2027, which should drive patients to direct-to-consumer telehealth providers like Hims & Hers. The stock's RSI is overbought at 70.86, and Wall Street remains bearish with only 4 of 16 analysts rating it a Buy, suggesting a pullback could present a better entry point for long-term investors.